Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy

Investigational New Drugs

Volumn 24, Issue 4, 2006, Pages 359-363

  Patel, Hitendra ^a   Stoller, Ronald ^a   Auber, Miklos ^b   Potter, Douglas ^a,c   Cai, Chao ^a   Zamboni, William ^d   Kiefer, Gauri ^a   Matin, Khalid ^a   Schmotzer, Amy ^a   Ramanathan, Ramesh K ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Phase II; Rubitecan

Indexed keywords

BILIRUBIN; FLUOROURACIL; RUBITECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CYSTITIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVALUATION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33646500157     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-6451-2     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30
2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
4. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Superiority of oxaliplatin and fluorouracilleucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracilleucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069
5. Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, Hua A, Mery-Mignard D (2002) Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 13:1558-1567
6. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418
7. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048
8. Bernacki RJ, Pera P, Gambacorta P, Brun Y, Greco WR (2000) In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs. Ann N Y Acad Sci 922:293-297
9. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469
10. Schneider E, Hsiang YH, Liu LF (1990) DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149-183
11. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914
12. Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361:2235-2242
13. Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K, Stehlin JS (1998) A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9:36-44
14. Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP (1997) 9-Aminocamptothecin by 72-h continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer 80:1727-1732
15. Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EE (2004) 9-Aminocamptothecin (9-AC) given as a 120-h. continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs 22:323-327
16. Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, Fakih M, Zamboni WC (2004) Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemother Pharmacol 54:487-496
17. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. Geneva: WHO
18. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
19. Schoffski P, Herr A, Vermorken JB, Van den BJ, Beijnen JH, Rosing H, Volk J, Ganser A, Adank S, Botma HJ, Wanders J (2002) Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 38:807-813
20. Pazdur R, Diaz-Canton E, Ballard WP, Bradof JE, Graham S, Arbuck SG, Abbruzzese JL, Winn R (1997) Phase II trial of 9-aminocamptothecin administered as a 72-h continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 15:2905-2909
21. Stehlin JS, Giovanella BC, Natelson EA, De Ipolyi PD, Coil D, Davis B, Wolk D, Wallace P, Trojacek A (1999) A study of 9-nitrocamptothecin (RES-2000) in patients with advanced pancreatic cancer. Int J Oncol 14:821-831
22. Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MM, Fakih M, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK (2004) Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clin Cancer Res 10:5058-5064
23. Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ (2000) Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 6:2685-2689
24. Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF (1999) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 43:454-460
25. Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML (1999) Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685-696